Breaking News Instant updates and real-time market news.

CARA

Cara Therapeutics

$15.27

-0.38 (-2.43%)

, AMGN

Amgen

$168.61

-11.5 (-6.39%)

04:55
03/19/17
03/19
04:55
03/19/17
04:55

American Academy of Pain Medicine to hold annual meeting

33rd Annual Meeting of AAPM is being held in Orlando, FL on March 15-19.

CARA

Cara Therapeutics

$15.27

-0.38 (-2.43%)

AMGN

Amgen

$168.61

-11.5 (-6.39%)

BDSI

BioDelivery Sciences

$1.90

-0.1 (-5.00%)

BSX

Boston Scientific

$24.43

0.14 (0.58%)

DEPO

Depomed

$15.78

-0.33 (-2.05%)

DGX

Quest Diagnostics

$99.06

0.34 (0.34%)

ENDP

Endo

$10.76

0.1 (0.94%)

JAZZ

Jazz Pharmaceuticals

$134.77

-1.08 (-0.79%)

MDXG

MiMedx

$8.85

0.19 (2.19%)

MDT

Medtronic

$82.23

0.4 (0.49%)

SYK

Stryker

$132.66

1.16 (0.88%)

TEVA

Teva

$33.64

-0.29 (-0.85%)

WTKWY

Wolters Kluwer

$41.30

0.41 (1.00%)

  • 20

    Mar

  • 21

    Mar

  • 23

    Mar

  • 24

    Mar

  • 03

    Apr

  • 04

    May

  • 30

    May

  • 07

    Jun

  • 19

    Jul

  • 30

    Aug

CARA Cara Therapeutics
$15.27

-0.38 (-2.43%)

12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
03/10/17
JANY
03/10/17
NO CHANGE
Target $20
JANY
Buy
Cara Therapeutics price target raised to $20 from $18 at Janney Capital
Janney Capital analyst Ken Trbovich highlighted that results from Part A of Cara Therapeutics' uremic pruritus study are expected later this month and that the company anticipates reporting results from its Phase 2b study in osteoarthritis pain and an interim analysis from the adaptive Phase 3 study in postoperative pain in Q2. He raised his fair value estimate for Cara shares to $20 from $18 ahead of these potential catalysts and keeps a Buy rating on the stock.
10/13/16
HCWC
10/13/16
INITIATION
Target $20
HCWC
Buy
Cara Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Cara Therapeutics with a Buy rating and $20 price target. The company's CR845 presents an opportunity treat peripheral pain without addiction potential, the analyst contends.
AMGN Amgen
$168.61

-11.5 (-6.39%)

03/17/17
OPCO
03/17/17
NO CHANGE
OPCO
Outperform
Amgen oversold on cholesterol data, says Oppenheimer
Oppenheimer analyst Leah Rush Cann says shares of Amgen are oversold after the FOURIER study of Repatha in patients with cardiovascular disease met its key endpoint. The risk reduction grew to 25% after one year on Repatha therapy, which is a "very important result," Cann tells investors in a research note. She believes the current stock price reflects little to no sales of Repatha through 2020. The analyst has an Outperform rating on Amgen, which is trading down 6% to $168.68.
03/17/17
NEED
03/17/17
NO CHANGE
Target $25
NEED
Strong Buy
Needham calls Esperion selloff on Amgen data 'counter-intuitive'
Needham analyst Chad Messer believes the selloff in shares of Esperion Therapeutics (ESPR) based on Amgen's (AMGN) Repatha's data is "counter-intuitive." The fact that there was a statistically significant benefit confirms that LDL reductions prevent heart attacks and strokes, Messer tells investors in a research note. Bempedoic acid will likely be priced more in line with other oral cholesterol therapies, which makes the value debate for PCSK9 drugs a positive for Esperion, not a negative, the analyst contends. The analyst keeps a Buy rating on Esperion with a $25 price target.
03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
03/17/17
PIPR
03/17/17
NO CHANGE
PIPR
Overweight
Amgen weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer recommends using today's weakness in shares of Amgen as a buying opportunity. The analyst believes Amgen can still turn Repatha into a $5B-plus product and he reiterates an Overweight rating on the shares.
BDSI BioDelivery Sciences
$1.90

-0.1 (-5.00%)

05/11/16
CANT
05/11/16
DOWNGRADE
Target $5
CANT
Hold
BioDelivery Sciences downgraded to Hold from Buy at Cantor
Cantor Fitzgerald analyst Chiara Russo downgraded BioDelivery Sciences to Hold and lowered her price target for the shares to $5 from $9. The analyst sees "decreased clarity" on top-line growth and disagrees with management's decision to enhance profitability via cutting SG&A rather than R&D.
09/23/16
JANY
09/23/16
UPGRADE
Target $4
JANY
Buy
BioDelivery Sciences upgraded to Buy from Neutral at Janney Capital
Janney Capital analyst Ken Trbovich upgraded BioDelivery Sciences (BDSI) to Buy from Neutral, stating that Endo International (ENDP) has "not yet announced, but clearly won" preferred status for Belbuca relative to market leader Butrans on United Healthcare's Prescription Drug List. Endo's Belbuca utilizes BioDelivery Sciences' patented BioErodible MucoAdhesive drug delivery technology. The United contract, paired with the fact that BioDelivery has announced five contract wins for Bunavail since July, put Bunavail on a path to show meaningful growth in 2017, said Trbovich, who maintains his $4 fair value estimate on the stock.
09/23/16
09/23/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) upgraded to Overweight from Equal Weight by Barclays analyst Karen Short, who assumed coverage of Wal-Mart and upped the price target for the shares to $87 from $70. Wal-Mart is Short's top pick in the sector, as she believes the retailing giant's "re-emergence as a disruptor" has the potential to "wreak havoc" on many companies in the space. 2. Cabot Oil & Gas (COG) upgraded two notches to Strong Buy from Market Perform by Raymond James analyst Kevin Smith, who said Cabot has improving fundamentals, a "prolific" growth outlook, and an attractive valuation. 3. BioDelivery Sciences (BDSI) upgraded to Buy from Neutral by Janney Capital analyst Ken Trbovich, who said that Endo International (ENDP), which uses BioDelivery's drug delivery technology, has "not yet announced, but clearly won" preferred status for Belbuca relative to market leader Butrans on United Healthcare's Prescription Drug List. 4. Packaging Corp. (PKG) upgraded to Buy from Hold by Deutsche Bank analyst Debbie Jones, citing an "improved earnings trajectory" following the TimBar acquisition. The analyst raised her price target for the shares to $90 from $77. 5. Prudential Financial (PRU) upgraded to Conviction Buy from Neutral by Goldman Sachs analyst Michael Kovac, who says his earnings estimates are now above consensus due to favorable equity markets, slowing rate pressure and lower currency headwinds. He expects Prudential's earnings to grow 10% in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BSX Boston Scientific
$24.43

0.14 (0.58%)

02/23/17
STFL
02/23/17
NO CHANGE
STFL
Buy
Boston Scientific shares defended at Stifel
02/24/17
LEER
02/24/17
NO CHANGE
LEER
Outperform
Selloff in Boston Scientific shares 'overdone,' says Leerink
Leerink analyst Danielle Antalffy believes the selloff in Boston Scientific's shares was "overdone" and would recommend buying on weakness following the announcement of a Lotus recall in Europe and 2-quarter delay in U.S. PMA filing/approval. The analyst believes the impact from the Lotus recall is limited, and reiterates an Outperform rating on the shares.
02/14/17
WELS
02/14/17
NO CHANGE
WELS
Medtronic data likely to be positive, says Wells Fargo
Wells Fargo predicts that data on Medtronic's (MDT) CoreValve/Evolut R, due to be presented on March 17, will show that the device "is superior to surgical aortic valve replacement in intermediate risk patients." If the results come in as expected, the device should be approved in the U.S. by early fall, according to the firm. Wells Fargo adds that the data should also be a positive for other TAVR stocks, including Edwards Lifesciences (EW) and Boston Scientific (BSX). Wells keeps Outperform ratings on all three stocks.
03/08/17
SBSH
03/08/17
NO CHANGE
SBSH
Citi getting more bullish on Medtronic after electrophysiologist survey
Citi analyst Amit Hazan says his firm's U.S. electrophysiologist survey shows slightly better than expected cardiac rhythm therapies volume growth, less share loss for Medtronic (MDT) than expected and modest share gains for Boston Scientific (BSX). The survey is most positive for Medtronic relative to CRM expectations, Hazan tells investors in a research note. He notes that the company is increasingly becoming one of his favorite stocks in the group. Hazan has a Buy rating on Medtronic with a $93 price target.
DEPO Depomed
$15.78

-0.33 (-2.05%)

02/20/17
MZHO
02/20/17
DOWNGRADE
Target $17
MZHO
Neutral
Depomed downgraded to Neutral from Buy at Mizuho
Mizuho analyst Irina Koffler downgraded Depomed to Neutral and lowered its price target to $17 from $24 saying her conviction in a takeout has diminished. The analyst said the timeline for the previously expected deal close has been pushed too far for comfort and now sees a 50% probability of a takeout at $23/share, from $25/share, versus 90% probability perviously. Koffler said without this deal there is also potential for management turnover due to activist involvement that could lead to a decline in shares.
02/21/17
02/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dick's Sporting (DKS) downgraded to Perform from Outperform at Oppenheimer by analyst Brian Nagel ahead of its upcoming earnings report, as he is increasingly concerned after a large number of leading sporting goods manufacturers and retailers reported results well shy of expectations, all while certain industry-wide sales trackers also hinted at top-line disruptions for the sector. 2. Mobileye (MBLY) downgraded to Neutral from Buy, as analyst Alex Veytsman said expectations are high and valuation largely reflects its strong growth profile. 3. Freeport McMoRan (FCX) downgraded to Sell from Hold at Deutsche Bank by analyst Chris Terry following news that the company failed to reach an agreement to export copper concentrate from Indonesia. The analyst now assumes that Grasberg operates on scaled-back mode, only supplying the local Gresik smelter for the remainder of 2017. He cut his price target for Freeport shares to $12.50 from $14. 4. Lumos Networks (LMOS) downgraded to Hold from Buy at Jefferies by analyst Scott Goldman citing the takeover by EQT Infrastructure, stating he does not expect any competing bids and sees "virtually no deal risk from a regulatory standpoint." 5. Depomed (DEPO) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/27/17
JANY
02/27/17
NO CHANGE
Target $26
JANY
Buy
Janney says Depomed has potential $200M reward in Purdue suit with little risk
Janney Capital analyst Ken Trbovich noted that Depomed has filed an amended complaint claiming Purdue willfully violated its patents with its abuse-deterrent formulation of OxyContin. Trbovich continues to think a damage award of $200M or more is possible, "with little to no downside risk" to Depomed, and keeps a Buy rating on the Depomed shares with a $26 fair value estimate.
02/14/17
02/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Depomed (DEPO) downgraded to Neutral from Buy at Mizuho, as analyst Irina Koffler said her conviction in a takeout has diminished. Koffler said without a deal there is also potential for management turnover due to activist involvement, which could lead to a decline in shares... 2. Aviragen (AVIR) downgraded to Neutral from Buy at Ladenburg by analyst Kevin DeGeeter after vapendavir failed to demonstrate an improvement in asthma symptoms. The analyst expects the company to discontinue development of vapendavir in asthmatics and re-evaluate plans for a Phase IIb study in hematopoietic stem cell transplant recipients... 3. Taylor Morrison (TMHC) downgraded to Market Perform from Outperform at FBR Capital, with Alex Rygiel citing valuation... 4. Hibbett Sports (HIBB) downgraded to Equal Weight from Overweight at Stephens, to Hold from Buy at SunTrust, and to Neutral from Positive at Susquehanna following a Q4 preannouncement that missed expectations and disappointing guidance... 5. Popeyes (PLKI) downgraded to Neutral from Buy at Sidoti. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DGX Quest Diagnostics
$99.06

0.34 (0.34%)

03/14/17
GSCO
03/14/17
UPGRADE
Target $113
GSCO
Conviction Buy
Quest Diagnostics upgraded to Conviction Buy from Buy at Goldman
Goldman Sachs analyst Isaac Ro upgraded Quest Diagnostics to Conviction Buy and raised his six-month price target for the shares to $113 from $101. The company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time, Ro tells investors in a research note. He believes Quest's ability to gain market share is not factored into consensus estimates.
03/16/17
03/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Oracle (ORCL) was upgraded to Market Perform from Underperform at JMP Securities and to Overweight from Neutral at JPMorgan. 2. GoPro (GPRO) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the recent stabilization in revenue as well as the company's "significant" restructuring initiatives accelerate its path to profitability to 2017 from 2019. These developments should, at the very least, stave off the bear scenario for a few quarters, Kovler tells investors in a research note. He raised his price target for GoPro shares to $9 from $8. 2. TJX (TJX) upgraded to Conviction Buy from Buy at Goldman with analyst Matthew Fassler saying the company offers long-term secular growth along with near-term catalysts. The analyst expects TJX to grow market share at the expense of department stores. 4. Inovio (INO) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy saying it has multiple earlier stage programs moving forward with more significant data points coming in 2017 while it moves closer to its pivotal study in cervical dysplasia. He notes that his model assumes that VGX-3100 is commercialized in 2021 for cervical dysplasia. 5. Quest Diagnostics (DGX) upgraded to Neutral from Underperform at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/17
03/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris upgraded saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118. 2. Dick's Sporting (DKS) upgraded to Outperform from Peer Perform at Wolfe Research. 3. Quest Diagnostics (DGX) upgraded to Conviction Buy from Buy at Goldman with analyst Isaac Ro saying the company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time. 4. Olympic Steel (ZEUS) and Reliance Steel (RS) were upgraded to Outperform from Neutral at Macquarie, while Worthington (WOR) was upgraded to Neutral from Underperform. 5. Ethan Allen (ETH) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch double upgrading the company saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/17
BOFA
03/16/17
UPGRADE
BOFA
Neutral
Quest Diagnostics upgraded to Neutral from Underperform at BofA/Merrill
ENDP Endo
$10.76

0.1 (0.94%)

02/21/17
ADAM
02/21/17
INITIATION
Target $14
ADAM
Hold
Endo initiated with a Hold at Canaccord
Canaccord analyst Dewey Steadman initiated Endo with a Hold and a $14 price target.
02/24/17
RHCO
02/24/17
NO CHANGE
RHCO
Avadel Pharmaceuticals price target lowered to $13 from $17 at SunTrust
SunTrust analyst John Boris reduced his price target on Avadel (AVDL) after Endo (ENDP) launched an injectable drug that will compete, at a similar price point, with Avadel's Akovaz. The analyst adds that Avadel's Bloxiverz is also being challenged by Merck's (MRK) Bridion which is taking share in the neostigmine market. He lowered his estimates for Avadel below consensus levels but keeps a Buy rating on the name.
02/22/17
02/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NVIDIA (NVDA) initiated with a Buy at Rosenblatt and with a Neutral at MKM Partners. 2. Intel (INTC) initiated with a Sell at Rosenblatt and a Buy at MKM Partners. 3. Goldman Sachs (GS) and Morgan Stanley (MS) initiated with a Neutral at Compass Point. 4. Endo (ENDP) initiated with a Hold at Canaccord. 5. Juno Therapeutics (JUNO) was initiated with an Outperform at Wells Fargo, while Kite Pharma (KITE) was initiated with a Market Perform. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/17
JEFF
01/31/17
NO CHANGE
Target $24
JEFF
Buy
Jefferies says new approvals now even more critical for Akorn
After Endo (ENDP) received approval for Corphedra, the second FDA approved formulation of ephedrine after Avadel Pharmaceuticals' (AVDL), Jefferies analyst David Steinberg says new product approvals are now even more critical to Akorn's (AKRX) 2017 outlook and share price. Both Endo and Avadel will compete with Akorn's largest product, Steinberg tells investors in a research note. His model assumes Akorn's ephedrine sales will decline to $80M in FY17 from $230M in FY16. The analyst keeps a Buy rating on Akorn, however, saying the shares look "very inexpensive" on "multiple valuation metrics."
JAZZ Jazz Pharmaceuticals
$134.77

-1.08 (-0.79%)

03/01/17
LEER
03/01/17
NO CHANGE
Target $170
LEER
Outperform
Jazz Pharmaceuticals price target lowered to $170 from $182 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Jazz Pharmaceuticals to $170 from $182 mainly due to lower Defitelio and terminal value assumptions. The analyst reiterates an Outperform rating on the shares.
03/13/17
JPMS
03/13/17
NO CHANGE
Target $190
JPMS
Overweight
JPMorgan continues to see attractive entry point in Jazz
After meeting with CFO Matt Young, JPMorgan analyst Jessica Fye says Jazz Pharmaceuticals remains one of her favorite stocks. She continues to believe that current stock levels offer an attractive entry point. The analyst expects "healthy" sales and earnings growth in 2017 as well as de-risking events around JZP-110, Vyxeos and potentially JZP-507. Fye keeps an Overweight rating on Jazz with a $190 price target.
03/01/17
COWN
03/01/17
NO CHANGE
Target $190
COWN
Outperform
Jazz Pharmaceuticals nearing an inflection point, says Cowen
Cowen analyst Ken Cacciatore believes Jazz Pharmaceuticals is nearing an interesting inflection point. He sees the Xyrem litigation extending the Jazz franchise to 2024/2025. With potential positive trial data coming, the shares could be nearing a complete re-rating, said Cacciatore, who reiterated his Outperform rating and $190 price targeted on Jazz shares.
02/23/17
02/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monsanto (MON) initiated with a Sector Perform at RBC Capital. 2. FMC Corporation (FMC) initiated with an Outperform at RBC Capital. 3. OncoCyte (OCX) initiated with a Buy at Chardan. 4. Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Evercore ISI. 5. Reata Pharmaceuticals (RETA) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MDXG MiMedx
$8.85

0.19 (2.19%)

12/12/16
FANA
12/12/16
NO CHANGE
FANA
Equal-Weight
First Analysis says reimbursement has favored MiMedx, but uncertainty exists
Under the current per-treatment reimbursement system, MiMedx (MDXG) has been a "powerhouse in wound care," taking share with its EpiFix product line, and current structure of the market naturally benefits MiMedx's business model, First Analysis analyst Joseph Munda tells investors. However, the FDA is reviewing the use and regulatory status of amniotic tissues in wound care and FDA action would raise their cost or limit their use, which is a risk for MiMedx that would likely benefit other advanced tissues, including Novadaq's (NVDQ) Dermacell, he contends. Munda keeps an Equal-Weight rating on MiMedx, citing regulatory uncertainties, and has an rate Overweight rating on Novadaq.
03/03/17
PIPR
03/03/17
INITIATION
Target $10
PIPR
Overweight
MiMedx initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien initiated MiMedx with an Overweight rating and $10 price target, calling it market leader for amniotic-based products that also has a large, untapped opportunity in pain management.
12/12/16
12/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ball Corp. (BLL) resumed with a Buy at Deutsche Bank. 2. Molson Coors (TAP) initiated with a Neutral at UBS. 3. Airgain (AIRG) initiated with an Outperform at Cowen. 4 Ritter Pharmaceuticals (RTTR) initiated with a Buy at Roth Capital. 5. MiMedx (MDXG) initiated with a Sell at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/16
UBSW
12/12/16
INITIATION
Target $9
UBSW
Sell
MiMedx initiated with a Sell at UBS
UBS analyst Matt Miksic started MiMedx Group with a Sell rating and $9 price target. The analyst says his firm's survey of 100 U.S. wound care specialists suggests Integra LifeSciences' (IART) Omnigraft launch will put competitive pressure on MiMedx's EpiFix over time. The stock at current levels is not discounting significant market share losses or decelerating growth, Miksic tells investors in a research note.
MDT Medtronic
$82.23

0.4 (0.49%)

02/23/17
LEER
02/23/17
NO CHANGE
Target $85
LEER
Market Perform
Medtronic price target raised to $85 from $80 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Medtronic to $85 from $80 after the company delivered what he believes was an "encouraging rebound" quarter after an unexpected Q2 miss. While the analyst remains cautious on the company's ability to manage through what could be meaningful top-line headwinds in Q4 and FY18 in order to deliver a targeted mid-single-digit sales growth, it does seem that the diversified business model gives it a cushion with which to offset underperforming business segments with stronger/faster growth elsewhere. He reiterates a Market Perform rating on the shares.
03/08/17
RBCM
03/08/17
NO CHANGE
RBCM
Edwards should be bought on any post-trial weakness, says RBC Capital
RBC Capital analyst Glenn Novarro estimates that there is a 70% chance of interim data showing that Medtronic's (MDT) CoreValve and CoreValve Evolut R are non-inferior to surgery and a 30% chance of the devices being shown to be superior to surgery. The analyst thinks that Edwards Lifesciences' stock will fall around 5% if the devices are shown to be non-inferior, and he believes that the stock will rise 5%-10% if it shown to be superior. However, the analyst believes that even a finding of non-inferiority will increase TAVR devices' market share, and he recommends buying Edwards on any pullback.
03/14/17
RBCM
03/14/17
NO CHANGE
RBCM
Medtronic pump delay a negative for United Therapeutics, says RBC Capital
After the FDA posted on its website that Medtronic (MDT) is recalling the SynchroMed Implantable Infusion Pumps because of a software problem, RBC Capital said this new recall may impact the timeline for United Therapeutics (UTHR) implantable pump. In March of last year, United Therapeutics said that Medtronic and the company were assessing a U.S. Food and Drug Administration response letter to Medtronic's premarket approval application, PMA, for the Remodulin Implantable System and measures to address the agency's concerns.
SYK Stryker
$132.66

1.16 (0.88%)

01/31/17
PIPR
01/31/17
NO CHANGE
Target $141
PIPR
Overweight
Zimmer Biomet guidance 'good enough,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said he views Zimmer Biomet's (ZBH) relatively in-line guidance for FY17 to be "good enough," adding that organic growth is seen accelerating throughout the year and that the company has both operating and financial levers to pull for earnings growth. O'Brien, who expects Zimmer's valuation discount to peer Stryker (SYK) to narrow, would be a buyer of Zimmer shares and keeps an Overweight rating on the stock.
01/11/17
LEER
01/11/17
NO CHANGE
Target $136
LEER
Outperform
Stryker price target raised to $136 from $127 at Leerink
Leerink analyst Richard Newitter raised his price target for Stryker to $136 from $127 after the company pre-announced a "solid" Q4 revenue beat and full year EPS that is anticipated to come in at the top-end of guidance. The analyst believes this "strong finish" to 2016 sets the tone for what he thinks will be continuing execution towards driving revenue growth at the top-end of MedTech. He reiterates an Outperform rating on the shares.
02/14/17
STFL
02/14/17
NO CHANGE
STFL
Survey on Stryker MAKO positive, says Stifel
Stifel analyst Rick Wise says that Stifel's survey of 82 U.S. hip and knee surgeons regarding Styker's MAKO device was "highly encouraging. The survey "reflected clearly significant surgeon interest in MAKO and the potential for material U.S. knee market share gains " for Styker," he added. The analyst raised his 2019-2020 U.S. knee growth rate projections for Stryker by about two percentage points per year and adds that the results show that the company's "momentum in MAKO is increasing." He believes that such momentum is an "essential" factor in the stock's ability to maintain its premium valuation and in the company's ability to maintain its "EPS trajectory." Wise keeps a $135 price target and a Buy rating on the shares.
01/25/17
ADAM
01/25/17
NO CHANGE
Target $137
ADAM
Buy
Stryker price target raised to $137 from $127 at Canaccord
Canaccord analyst Kyle Rose raised his price target on Stryker to $137 from $127 following its better than expected Q4 results. The analyst cited its organic growth and guidance of 5.5%-6.5% growth, which he views as conservative. He also sees upside to operating margins. Rose reiterated his Buy rating on Stryker shares.
TEVA Teva
$33.64

-0.29 (-0.85%)

02/28/17
ARGS
02/28/17
DOWNGRADE
ARGS
Hold
Teva downgraded to Hold from Buy at Argus
02/21/17
LEER
02/21/17
NO CHANGE
LEER
Outperform
Warning letter raises concerns on Momenta Copaxone catalyst, says Leerink
Leerink analyst Jason Gerberry notes that Momenta (MNTA) disclosed that its generic Copaxone 40mg ANDA will be delayed by an FDA warning letter at its fill-finish manufacturing partner, Pfizer (PFE). The analyst says that while a short delay to Momenta/Novartis' (NVS) g-Copaxone 40mg is not reason for concern, longer delays could diminish the market opportunity as there are four other generic challengers, but none have been able to prove bioequivalence to Teva's (TEVA) lower strength. He reiterates an Outperform rating on Momenta's shares.
02/28/17
02/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Workday (WDAY) downgraded to Sell from Neutral at Citi and to Hold from Buy at Evercore ISI. 2. Exelixis (EXEL) downgraded to Hold from Buy at Stifel with analyst Stephen Willey citing valuation. 3. Teva (TEVA) downgraded to Hold from Buy at Argus. 4. Cabot Oil & Gas (COG) downgraded to Market Perform from Outperform at Bernstein. 5. HP Enterprise (HPE) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/17
JEFF
03/07/17
NO CHANGE
Target $33
JEFF
Buy
Supernus settlement modestly better than expected, says Jefferies
Jefferies analyst David Steinberg says Supernus Pharmaceuticals (SUPN) should be able maintain exclusivity on 65% of Trokendi XR sales until January 2023 following its settlement with Zydus Pharmaceutical. The analyst views the settlement as modestly better than his forecast. Should Supernus secure a similar settlement with Teva (TEVA), it would be well positioned to transition the revenue stream from its current epilepsy franchises to two late-stage pipeline candidates, Steinberg tells investors in a research note. He keeps a Buy rating on Supernus with a $33 price target.
WTKWY Wolters Kluwer
$41.30

0.41 (1.00%)

03/10/17
GSCO
03/10/17
UPGRADE
GSCO
Neutral
Wolters Kluwer upgraded to Neutral from Sell at Goldman

TODAY'S FREE FLY STORIES

REGN

Regeneron

$369.14

-1.84 (-0.50%)

, GSK

GlaxoSmithKline

$42.28

-0.04 (-0.09%)

20:06
03/22/17
03/22
20:06
03/22/17
20:06
Hot Stocks
Regeneron announces 'major' gene sequencing effort with Glaxo, U.K. Biobank »

Regeneron (REGN)…

REGN

Regeneron

$369.14

-1.84 (-0.50%)

GSK

GlaxoSmithKline

$42.28

-0.04 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 29

    Mar

  • 06

    Jun

ALK

Alaska Air

$92.92

0.81 (0.88%)

19:51
03/22/17
03/22
19:51
03/22/17
19:51
Hot Stocks
Alaska Air outlines post-merger 'vision,' says enhancing several brand elements »

Alaska Airlines and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

FB

Facebook

$139.59

1.08 (0.78%)

19:35
03/22/17
03/22
19:35
03/22/17
19:35
Hot Stocks
Instagram says monthly active advertisers tops 1M »

Facebook's Instagram…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

FB

Facebook

$139.59

1.08 (0.78%)

, YELP

Yelp

$33.50

-0.12 (-0.36%)

19:30
03/22/17
03/22
19:30
03/22/17
19:30
Periodicals
Facebook tests enhanced local search feature, TechCrunch says »

Facebook (FB) is testing…

FB

Facebook

$139.59

1.08 (0.78%)

YELP

Yelp

$33.50

-0.12 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 05

    Jun

  • 08

    Jun

ZTCOY

ZTE Corp.

$3.77

0.05 (1.34%)

19:16
03/22/17
03/22
19:16
03/22/17
19:16
Hot Stocks
DOJ says ZTE Corp pleads guilty in Iran sanctions case »

The Justice Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$110.99

0.09 (0.08%)

19:12
03/22/17
03/22
19:12
03/22/17
19:12
Hot Stocks
Avtec says signs agreement with Harris on resale of dispatch consoles »

Avtec, a provider of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$7.98

-1.12 (-12.31%)

18:59
03/22/17
03/22
18:59
03/22/17
18:59
Periodicals
Sears suppliers taking 'defensive measures,' Reuters says »

Sears' suppliers are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$75.76

-0.22 (-0.29%)

18:33
03/22/17
03/22
18:33
03/22/17
18:33
Periodicals
German prosecutors investigate Daimler employees, Bloomberg says »

Daimler AG employees are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$30.42

0.33 (1.10%)

, FOXA

21st Century Fox

$30.97

0.41 (1.34%)

18:31
03/22/17
03/22
18:31
03/22/17
18:31
Periodicals
Studios continue negotiations on accelerated release windows, Variety says »

Six of the seven largest…

FOX

21st Century Fox

$30.42

0.33 (1.10%)

FOXA

21st Century Fox

$30.97

0.41 (1.34%)

TWX

Time Warner

$96.84

-0.63 (-0.65%)

LGF.A

Lionsgate

$24.98

0.5 (2.04%)

LGF.B

Lionsgate

$23.20

0.22 (0.96%)

VIA

Viacom

$44.20

0.45 (1.03%)

VIAB

Viacom

$42.57

0.47 (1.12%)

SNE

Sony

$31.98

0.22 (0.69%)

AMC

AMC Entertainment

$30.30

0.15 (0.50%)

RGC

Regal Entertainment

$21.90

-0.21 (-0.95%)

DIS

Disney

$112.08

0.33 (0.30%)

CMCSA

Comcast

$37.04

-0.03 (-0.08%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 03

    May

  • 04

    May

  • 25

    May

JRJR

JRjr33

$0.47

-0.01 (-2.08%)

18:05
03/22/17
03/22
18:05
03/22/17
18:05
Hot Stocks
JRjr33's plan to regain listing compliancy approved by NYSE »

JRjr33 has received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$829.59

-0.87 (-0.10%)

, GOOGL

Alphabet Class A

$849.80

-0.34 (-0.04%)

18:04
03/22/17
03/22
18:04
03/22/17
18:04
Hot Stocks
Google expands 'Posts on Google' test »

Google announced in a…

GOOG

Alphabet

$829.59

-0.87 (-0.10%)

GOOGL

Alphabet Class A

$849.80

-0.34 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 02

    May

  • 22

    May

CE

Celanese

$90.14

0.68 (0.76%)

18:02
03/22/17
03/22
18:02
03/22/17
18:02
Hot Stocks
Celanese increases price of vinyl acetate monomer in Asia »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$139.59

1.08 (0.78%)

17:51
03/22/17
03/22
17:51
03/22/17
17:51
Hot Stocks
Facebook rolls out 'header bidding' ad technology »

Facebook issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

FIVE

Five Below

$38.13

-0.72 (-1.85%)

, PVH

PVH Corp.

$90.85

-1.83 (-1.97%)

17:45
03/22/17
03/22
17:45
03/22/17
17:45
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Five…

FIVE

Five Below

$38.13

-0.72 (-1.85%)

PVH

PVH Corp.

$90.85

-1.83 (-1.97%)

BEBE

bebe stores

$3.86

0.29 (8.12%)

HTGM

HTG Molecular

$2.14

0.17 (8.63%)

HTBX

Heat Biologics

$1.03

0.04 (4.04%)

RARE

Ultragenyx

$78.36

0.64 (0.82%)

GPOR

Gulfport Energy

$16.10

-0.33 (-2.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

  • 01

    Apr

  • 06

    Jun

  • 20

    Jun

FNV

Franco-Nevada

$64.21

-1.33 (-2.03%)

17:36
03/22/17
03/22
17:36
03/22/17
17:36
Hot Stocks
Franco-Nevada sees 2021 oil and gas revenues of $55M-$65M »

Franco-Nevada expects its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

MSFT

Microsoft

$65.03

0.82 (1.28%)

17:35
03/22/17
03/22
17:35
03/22/17
17:35
Hot Stocks
LinkedIn introduces 'Trending Storylines' »

Microsoft's LinkedIn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

FNV

Franco-Nevada

$64.21

-1.33 (-2.03%)

17:35
03/22/17
03/22
17:35
03/22/17
17:35
Hot Stocks
Franco-Nevada sees 2017 revenue from oil & gas assets of $35M-$45M »

Franco-Nevada expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

CPB

Campbell Soup

$56.91

-0.18 (-0.32%)

17:34
03/22/17
03/22
17:34
03/22/17
17:34
Hot Stocks
Campbell Soup announces $1.5B share repurchase plan »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEO

Telecom Argentina

$22.26

-0.24 (-1.07%)

17:33
03/22/17
03/22
17:33
03/22/17
17:33
Syndicate
Breaking Syndicate news story on Telecom Argentina »

Telecom Argentina files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNV

Franco-Nevada

$64.21

-1.33 (-2.03%)

17:31
03/22/17
03/22
17:31
03/22/17
17:31
Earnings
Franco-Nevada reports Q4 adjusted EPS 24c, consensus 21c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

MYL

Mylan

$41.70

0.03 (0.07%)

17:26
03/22/17
03/22
17:26
03/22/17
17:26
Periodicals
Mylan recalls 81K EpiPens outside U.S., Reuters reports »

After reports of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 03

    Sep

  • 09

    Oct

CG

Carlyle Group

$15.80

0.05 (0.32%)

17:25
03/22/17
03/22
17:25
03/22/17
17:25
Conference/Events
CFA Society of Washington, D.C. to hold a dinner »

The CFA Society of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

PENN

Penn National

$15.39

-0.28 (-1.79%)

, CYNO

Cynosure

17:19
03/22/17
03/22
17:19
03/22/17
17:19
Hot Stocks
Penn National to replace Cynosure in S&P 600 at open on March 27 »

S&P 500 constituent…

PENN

Penn National

$15.39

-0.28 (-1.79%)

CYNO

Cynosure

HOLX

Hologic

$42.09

0.15 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 31

    Mar

  • 06

    Jun

FIVE

Five Below

$38.13

-0.72 (-1.85%)

17:16
03/22/17
03/22
17:16
03/22/17
17:16
Recommendations
Five Below analyst commentary at Loop Capital »

Five Below Q4 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 20

    Jun

ENPH

Enphase Energy

$1.24

-0.01 (-0.80%)

17:09
03/22/17
03/22
17:09
03/22/17
17:09
Syndicate
Breaking Syndicate news story on Enphase Energy »

Enphase Energy files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.